GlaxoSmithKline Pharmaceuticals Limited (GLAXO) — share transfer | 8 July 2026

· NSE Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings

GlaxoSmithKline Pharmaceuticals Limited received a SEBI-mandated share transfer agent certificate for the quarter ended June 30, 2026, confirming dematerialized securities were accepted and listed on exchanges, with registered ownership updated within 30 days.

📄 View Original Announcement (PDF)

About GlaxoSmithKline Pharmaceuticals Limited (GLAXO)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹51,721.36 Cr P/E: 49.2 ROE: 47.1% ROCE: 64.1% Div Yield: 1.87%

View full GLAXO stock details →

📡 Get AI alerts when GLAXO files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track GLAXO — Free

📊 More GLAXO filings

See all GLAXO filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when GLAXO files new disclosures

Track GLAXO filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track GLAXO — Free

Free account · 2 AI queries/day